The M6A Polyclonal Antibody (AGEL3800) is a versatile tool for researchers studying the role of N6-methyladenosine (m6A) modification in RNA biology. This antibody, produced against the m6A modification, is highly specific and sensitive, making it suitable for a variety of applications including immunoprecipitation, immunofluorescence, and RNA immunoprecipitation sequencing (RIP-seq). The m6A modification is a common post-transcriptional RNA modification that plays a crucial role in regulating gene expression, mRNA stability, and protein translation. Dysregulation of m6A modification has been linked to various diseases, including cancer, neurodegenerative disorders, and metabolic disorders.
By using the M6A Polyclonal Antibody, researchers can investigate the dynamic changes of m6A modification in different cellular contexts, providing valuable insights into the molecular mechanisms underlying disease development and progression.Overall, the M6A Polyclonal Antibody is a powerful tool for researchers interested in elucidating the functional significance of m6A modification in RNA metabolism and disease pathology. Its high specificity and sensitivity, coupled with its versatility in various experimental techniques, make it a valuable asset for advancing our understanding of the role of m6A modification in health and disease.
Product Title:
m6A Polyclonal Antibody
SKU:
AGEL3800
Size:
100µg
Clonality:
Polyclonal
Synonyms:
N6-methyladenosine
Host Species:
Rabbit
Reactivity:
E.coli
Application:
Dot blot
Isotype:
IgG
Recommended Dilution:
Dot Blot 1:500-1000
Conjugation:
Unconjugated
Immunogen:
N6-methyladenosine conjugated to KLH
Target:
m6A
Purification Method:
Antigen Affinity Purification
Concentration:
1mg/mL
Storage Buffer:
PBS with 0.02% sodium azide,1% protective protein and 50% glycerol,pH7.4
Stability & Storage:
Store at -20℃. Avoid freeze / thaw cycles.
Background:
N6-methyladenosine (m6A) is the most prevalent, abundant and conserved internal cotranscriptional modification in eukaryotic RNAs, especially within higher eukaryotic cells. Recent studies have shown that m6A RNA modification plays essential role in both physiological and pathological conditions, especially in the initiation and progression of different types of human cancers.
